Tag: Europe
-
Trial Shows Synthetic Antibody Slows Cognitive Decline
Results show a synthetic antibody reduces the rate of cognitive decline, one of two measures in a clinical trial of patients with mild to moderate Alzheimer’s disease.
-
Trial Shows Wearable Device Monitors Heart Rhythm Indicators
Results from a clinical trial show a device worn on the wrist can measure two key indicators of heart health as accurately as an electrocardiogram.
-
AI-Analyzed Liquid Biopsy IDs Early Lung Cancer
A blood test analyzed with algorithms is shown to detect more than 90 percent of early-stage lung cancer cases in people at high risk of the disease.
-
CEPI Funding Covid-19 Variant Vaccine
A biotechnology company is advancing a vaccine to protect against disease from SARS-CoV-2 variants, with new support from the organization CEPI.
-
Protein Chemistry Biotech Acquired in $2B Deal
Drug maker Bayer is acquiring a company discovering new therapies with a technology that reveals complex protein targets considered difficult to address.
-
Sanofi Acquires mRNA Developer in $3.2B Deal
Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and therapies, and a long-time collaborator.
-
Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal
A French biopharmaceutical company is gaining access to a technology using synthetic nucleic acids to treat rare genetic neurological diseases.
-
Trial Tests Psychedelic Drug Safety, Chemical Activity
A clinical trial is underway that tests an hallucinogenic compound among healthy adults as a potential treatment for mental health disorders.
-
Synthetic Blood Vessel Maker Gains $2.2M in Seed Funds
A start-up company creating synthetic blood vessels for transplants, based on research in materials science and cell biology, is raising $2.2 million in seed funds.
-
Neuro Disease Start-Up Raises $73M in Early Funds
A new enterprise discovering treatments for neurodegenerative diseases is merging with another start-up and raising $73 million its first venture round.